FOX04-DRI – Powder

FOXO4-DRI – D-Retro-Inverso Peptide | 10 mg

FOXO4-DRI (D-retro-inverso FOXO4 peptide) is a synthetic, cell-permeable peptide engineered to selectively induce apoptosis in senescent cells by disrupting the interaction between FOXO4 and p53. This disruption leads to nuclear exclusion of p53 and activation of mitochondrial apoptosis pathways, sparing healthy, non-senescent cells. It was developed based on research conducted at Erasmus Medical Center in the Netherlands and has since become a widely used research compound in the study of cellular senescence and aging.

Key Research Findings:

• Cellular senescence: Induces apoptosis in senescent human fibroblasts (IMR90) with minimal effect on non-senescent cells (Baar et al., 2017).
• Cartilage repair: Eliminates senescent chondrocytes, improving regenerative quality in autologous chondrocyte implantation models (Lee et al., 2021).
• Reproductive aging: Restores testosterone levels and spermatogenesis in aged mice by clearing senescent Leydig cells (Qin et al., 2022).
• Scar biology: Selectively targets senescent keloid fibroblasts without affecting healthy tissue (Yoshida et al., 2021).
• Oncology research: Shown to sensitize cancer-associated fibroblasts to radiation by removing senescence-associated resistance (Chu et al., 2023).
  
  

Specifications:

• CAS Number: 2460055-10-9
• Peptide Type: D-retro-inverso peptide (includes a TAT cell-penetrating sequence)
• Sequence: H–D-Arg–D-Lys–D-Gly–D-Tyr–D-Gly–D-Arg–D-Lys–D-Leu–D-Gly–D-Lys–D-Gln–D-Leu–D-Glu–D-Gly–D-Asp–D-Tyr–D-Gly–D-Lys–NH₂
• Molar Mass: ~2124.5 g/mol (depends on exact sequence and salt form)
• Purity: ≥99% (HPLC)
• Form: Lyophilized powder
• Amount: 10 mg per vial (other quantities available upon request)
• Storage:
  • Short-term: 2–8 °C
  • Long-term: –20 °C, protected from light and moisture
  • Reconstituted: Store at 2–8 °C and use within 30 days